tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Simcere Licenses Global Rights to Cancer ADC SIM0613 to Ipsen in US$1.06 Billion Deal
PremiumCompany AnnouncementsSimcere Licenses Global Rights to Cancer ADC SIM0613 to Ipsen in US$1.06 Billion Deal
2M ago
Simcere’s ENZESHU® and ENDOSTAR® Included in China’s National Reimbursement Drug List
Premium
Company Announcements
Simcere’s ENZESHU® and ENDOSTAR® Included in China’s National Reimbursement Drug List
3M ago
Simcere Secures Exclusive License for Deuterated Remdesivir Hydrobromide
Premium
Company Announcements
Simcere Secures Exclusive License for Deuterated Remdesivir Hydrobromide
3M ago
Simcere Pharmaceutical’s SIM0609 Receives Clinical Trial Approval
PremiumCompany AnnouncementsSimcere Pharmaceutical’s SIM0609 Receives Clinical Trial Approval
6M ago
Simcere’s Pediatric Anti-Influenza Drug Gains Regulatory Nod
Premium
Company Announcements
Simcere’s Pediatric Anti-Influenza Drug Gains Regulatory Nod
6M ago
Simcere Pharmaceutical Announces Share Placing and Subscription Agreement
Premium
Company Announcements
Simcere Pharmaceutical Announces Share Placing and Subscription Agreement
6M ago
Simcere Pharmaceutical Enhances Governance with New Nomination Committee
PremiumCompany AnnouncementsSimcere Pharmaceutical Enhances Governance with New Nomination Committee
6M ago
Simcere Pharmaceutical Schedules Board Meeting to Review Interim Results
Premium
Company Announcements
Simcere Pharmaceutical Schedules Board Meeting to Review Interim Results
7M ago
Simcere’s Rademikibart NDA Accepted by China’s NMPA
Premium
Company Announcements
Simcere’s Rademikibart NDA Accepted by China’s NMPA
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100